Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Livzon Pharmaceutical Group ( (HK:1513) ).
Livzon Pharmaceutical Group has announced that its Recombinant anti-human IL-17A/F Humanized Monoclonal Antibody Injection, developed in collaboration with Beijing Kanova Biopharmaceutical, has achieved the primary endpoint in a phase III clinical trial for moderate-to-severe plaque psoriasis. The trial results demonstrated that the drug, LZM012, is non-inferior and even superior to the control drug secukinumab, with a faster onset of action and sustained benefits over time. The company is advancing towards market launch by submitting an application to the National Medical Products Administration, which could enhance its positioning in the psoriasis treatment market.
The most recent analyst rating on (HK:1513) stock is a Hold with a HK$30.00 price target. To see the full list of analyst forecasts on Livzon Pharmaceutical Group stock, see the HK:1513 Stock Forecast page.
More about Livzon Pharmaceutical Group
Livzon Pharmaceutical Group is a company involved in the pharmaceutical industry, focusing on the development and production of therapeutic biological products. Its primary products include humanized monoclonal antibody injections, with a market focus on innovative treatments for conditions like psoriasis.
YTD Price Performance: 42.04%
Average Trading Volume: 1,889,324
Technical Sentiment Signal: Buy
Current Market Cap: HK$38.75B
For a thorough assessment of 1513 stock, go to TipRanks’ Stock Analysis page.